The Gateway Hemophilia Association

is a nonprofit, community-based organization, dedicated to the advocacy, education, and support of families affected by bleeding disorders.

An Introduction to Bleeding Disorders

Hemophilia

Hemophilia is primarily an inherited disorder that does not allow blood to clot properly. There is a deficiency in the body of the necessary proteins, also called clotting factors, needed to stop bleeding. Hemophilia A is the deficiency of clotting factor VIII and according to the US Centers for Disease Control and Prevention (CDC), hemophilia occurs in approximately 1 in 5,617 male births.

Hemophilia B is the deficiency of clotting factor IX and affects about 1 in 25,000 males.

Von Willebrands

VWD is the most common bleeding disorder, found in up to 1% of the U.S. population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease. Although VWD occurs among men and women equally, women are more likely to notice the symptoms because of heavy or abnormal bleeding during their menstrual periods and after childbirth. There are 3 major types of VWD: Type 1, Type 2, and Type 3.

Upcoming Events

12/07/2023

Join us to learn more about switching it up with ALTUVIIIO

The Train Shed

201 S 18th St, St. Louis, MO 63103

Start Time: 6:15 p.m.

Learn more about factor activity levels and the benefits and safety of a once-weekly treatment. This educational program provides an interactive, engaging experience sponsored by Sanofi. A Community Relations and Education (CoRe) Manager, Kyrie Smith will provide an understanding about the role of factor activity levels and information about what this treatment option could mean for your management plan. Reply by 12/4 to carly@gatewayhemophilia.org.Parking will be validated.

Also hear from David who will share his story and experience on Altuviiio.

Switch it up with ALTUVIIIO

ALTUVIIIO and Sanofi are trademarks of Sanofi or an affiliate.
INDICATION: ALTUVIIIOTM [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

12/20/2023